Daphne Zohar is the co-founder and CEO of PureTech, a Boston-based firm specializing in translating breakthrough research from top tier academic institutions into therapies that will impact human health and well-being. PureTech’s senior partners include entrepreneurs and leaders from the highest echelon of pharma, biotech and academia. Ms. Zohar was named one of the world's top young innovators who will shape the future of technology by MIT's Technology Review magazine and one of the top "40 under 40" by the Boston Business Journal. A successful entrepreneur, Zohar created PureTech and assembled a leading team to help implement her vision for the firm. She co-founded and sits on the Boards of Directors of PureTech, Solace Pharmaceuticals (where she was founding CEO), Follica Inc. (where she was founding CEO), Enlight Biosciences (a technology development company whose backers include Merck, Pfizer, Lilly, Johnson & Johnson, and Novartis), Endra, and Satori Pharmaceuticals (where she was founding CEO). She also sits on the Technology Development Fund Advisory Board at Children's Hospital Boston, the Tufts University School of Medicine Advisory Committee for Drug Discovery and Development, and is an editorial advisor to Xconomy, a national technology news blog.
A lot of people have been asking lately if the venture model is broken. But it seems to me that it’s just decrepit. Like an aging, rotund former football star, the... Read more »
Am interested to hear what people think about this website (www.thefunded.com) where entrepreneurs rank venture funds. I like the concept of shifting the power dynamic and keeping venture funds... Read more »
I believe the proposed patent reform act would stifle innovation, which already has many hurdles to overcome, particularly in the earliest stages (when foundational patents are filed). To arbitrarily limit damages... Read more »
June 12, 2018
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.